Abstract:Background Pembrolizumab has robust antitumor activity in advanced melanoma and has been approved for the treatment of melanoma in many countries. Adjuvant pembrolizumab was associated with longer recurrence-free survival (RFS) in patients with resected stage III melanoma. We herein report on the RFS outcomes of Chinese patients with resected stage III melanoma receiving adjuvant pembrolizumab in comparison to those receiving interferon alpha-2b (IFN-alpha-2b). Methods We retrospectively investigated the medical records of subjects with resected stage III melanoma with no in-transit metastases diagnosed who were treated at the Cancer Hospital of the University of Chinese Academy of Sciences and collected historical clinical data of patients receiving adjuvant IFN-alpha-2b therapy in our hospital. The RFS rates were evaluated using Kaplan-Meier curves, and the differences between the groups were tested using the log-rank test. Results A total of 29 patients receiving adjuvant pembrolizumab therapy and 27 patients receiving adjuvant IFN-alpha-2b therapy were enrolled. The median RFS was not reached (95% CI not estimable [NE]) in the pembrolizumab group and was 25 months in the IFN-alpha-2b group, and there was no significant difference in RFS between the pembrolizumab and IFN-alpha-2b groups (HR = 1.20, log-rank p = 0.75). There was no significant difference in RFS for acral melanoma between the pembrolizumab group and IFN-alpha-2b group (HR = 1.22, log-rank p = 0.79). For patients with IIIC or IIID melanoma, the RFS in the pembrolizumab group was also similar to that of the IFN-alpha-2b group (HR = 0.80, log-rank p = 0.47). The RFS for patients receiving pembrolizumab with programmed cell death ligand 1 (PD-L1)-positive tumors might tend to be longer than that for patients with PD-L1-negative tumors, but there was no significant difference between the groups (HR = 3.37, log-rank p = 0.17). High tumor mutational burden (TMB) did not reveal a trend to predict a longer RFS than low TMB in patients receiving pembrolizumab (HR = 1.63, log-rank p = 0.63). Grade 3-4 adverse events occurred in 6 (22.22%) of 27 patients in the IFN-alpha-2b group. Discontinuations attributed to adverse events (AEs) occurred in 2 patients treated with IFN-alpha-2b. Immune-related adverse events were observed in 5 (17.24%) patients in the pembrolizumab group. In the pembrolizumab group, grade 3-4 adverse events occurred in 2 (6.90%) patients, 1 of which required the discontinuation of a study drug and corticosteroid treatment. None of the patients discontinued treatment due to treatment-related or immune-mediated AEs. Conclusions Adjuvant pembrolizumab appeared to be as effective as IFN-alpha-2b in prolonging RFS in Chinese patients with resected stage III melanoma. Adjuvant pembrolizumab was associated with a lower rate of treatment-related AEs than IFN-alpha-2b. A prospective study is needed to confirm the clinical benefit of adjuvant pembrolizumab and determine dependable biomarkers.

Impact of Adjuvant Interferon Therapy on Survival Outcomes for Cutaneous Melanoma With Parotid Involvement

Oncological Outcome of Patients with Salivary Gland Cancer Treated with Surgery and Postoperative Intensity-Modulated Radiotherapy: a Retrospective Study

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684

Impact of Adjuvant Therapy on Survival for Sinonasal Mucosal Melanoma

Phase Ii Randomized Study of High-Dose Interferon Alfa-2b (hdi) Versus Chemotherapy As Adjuvant Therapy in Patients with Resected Mucosal Melanoma

Adjuvant radiotherapy plus systemic chemotherapy in resected head and neck mucosal melanoma.

Intravenous High-Dose Interferon With Or Without Maintenance Treatment In Melanoma At High Risk Of Recurrence: Meta-Analysis Of Three Trials

High-dose interferon is the first choice for postoperative adjuvant therapy of melanoma patients:An observation of 450 samples

Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer

The Impact of Preoperative Facial Nerve Weakness and Facial Nerve Outcomes in the Management of Patients With Parotid Metastases of Cutaneous Squamous Cell Carcinoma

The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

Surgical Management of Patients with Parotid Involvement from Non-Melanoma Skin Cancer of the Head and Neck

Survival in Patients with Primary Parotid Gland Carcinoma after Surgery-Results of a Single-Centre Study

Adjuvant Pembrolizumab Versus High-Dose Interferon Α-2B for Chinese Patients with Resected Stage III Melanoma: a Retrospective Cohort Study.

Efficacy and Safety of Postoperative Adjuvant Radiation Therapy in Resected Nasal Cavity and Paranasal Sinus Mucosal Melanoma: A Combined Analysis.

Real-World Survival Impact and Utilization of Adjuvant Radiation in Advanced Laryngeal Cancer

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma

Adjuvant Radiotherapy in Surgically Treated HPV-Positive Oropharyngeal Carcinoma with Adverse Pathological Features

Head and Neck Merkel Cell Carcinoma: Therapeutic Benefit of Adjuvant Radiotherapy for Nodal Disease

Deciphering the role of adjuvant therapy in melanoma and its actual benefits